Mental health AI
Ash
Ash offers patient-chosen mental health conversations. Published conditions describe opt-in improvement use, whose implementation was not tested. Its qualified agency finding does not establish clinical effectiveness or control over every therapeutic goal.
Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.
Agency checklist · October 30, 2026
Leans expands 8 of 12 yes
Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.
Assessed function: Slingshot AI's adult consumer emotional-support app Ash, with self-directed or AI-guided conversations. A vendor-controlled self-help service, not professional therapy or crisis response.
A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.
- Public documents do not establish actual product behavior.
- The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
| Question | Answer | Evidence / review | Source and reasoning |
|---|---|---|---|
| 1. Told it is AI | Yes | documented Not independently replicated | conversational techniques powered by an artificial intelligence powered technologySource The home page also says 'AI designed for mental health'. The EULA says outputs are 'susceptible to inaccuracies... including hallucinations'. |
| 2. Operator and model maker named | Yes | documented Not independently replicated | Slingshot built Ash, the first foundation model for psychology, on the cloud provider's infrastructureSource Slingshot AI, Inc. is the operator. Slingshot says it built its own model, with Nebius as infrastructure. The base model lineage is not disclosed. |
| 3. Patient chooses to use it | Yes | documented Not independently replicated | launched as a free iOS and Android download in July 2025Source The user downloads the app and starts. Subscription terms apply for paid features. |
| 4. Patient sets the task | Yes | documented Not independently replicated | Come with your own agenda or let Ash guide the way.Source The user can set the topic or choose AI-guided sessions. The AI-guided mode and the 'program' that Ash creates are Ash-directed, so a reviewer may weigh steering. |
| 5. Patient can decline or stop | Yes | documented Not independently replicated | launched as a free iOS and Android download in July 2025Source Self-started tool per the Q3 source, no care depends on it. |
| 6. Patient sees the AI output | Yes | documented Not independently replicated | your conversation history is available to you at any timeSource Voice is not retained as a recording beyond transcription. |
| 7. Patient can correct or challenge | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source The privacy policy lists correcting inaccurate personal information only 'depending on where you live'. No route to contest Ash output. |
| 8. Patient can get a copy | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source The policy says access to or a copy of personal information may be available depending on where you live, via email. No general export is documented. The app shows conversation history, which is viewing, not a copy. |
| 9. Patient can delete | Yes | documented Not independently replicated | you may request deletion by selecting “delete my data” in the Platform and confirming the selection.Source Deleting name and contact information requires deleting the account and emailing support. |
| 10. Training or sale does not override patient choice | Yes | documented Not independently replicated | We do not use your conversation transcripts to train or improve Ash, or make them available to our teamSource Opt-in only: the policy says 'unless you opt in to sharing them', and opted-in text is scrubbed of personal information. Opt-in data is also used for research with academic partners. |
| 11. Patient can run it or take it elsewhere | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source Vendor-hosted only. |
| 12. No advertising or data business | No | documented Not independently replicated | device and advertising identifiers, and analytics and attribution technologiesSource Conversation content is not shared with analytics or advertising partners, per the consumer health notice. But device and advertising identifiers and activity data go to analytics and attribution providers such as AppsFlyer, and the notice says Slingshot may 'use and share' de-identified data. Reviewer should confirm whether this counts as a data business. |
Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.
Checklist rules · Independent review and limitations · Later evidence follow-up
Earlier v1.3 assessment and control finding
Historical assessment under different rules. It does not set the current checklist zone.
Agency finding, before method v1.3
Mixed, access gains with unproven clinical claims
Legacy editorial placement, pre-method: 70
This profile has not yet been reviewed under the published method. Its finding and any number are editorial placements made before the method existed.
- Evidence
- Documentary review. Public sources only, no hands-on testing by HugoScore.
- Review status
- AI draft. No person has settled the findings.
Earlier evidence and assessment
The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.
Earlier finding · Legacy editorial placement, pre-method: 70
Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 70. Not comparable with v1.3 positions.
Mixed, access gains with unproven clinical claims
Ash offers patient-chosen mental health conversations. Published conditions describe opt-in improvement use, whose implementation was not tested. Its qualified agency finding does not establish clinical effectiveness or control over every therapeutic goal.
Patient agency
How this tool changes agency
Reflection and pattern suggestions may expand understanding, but claims that an AI has found a personal pattern need inspectable evidence and opportunities to disagree. Friendly language and engagement are insufficient proof.
Actual consent defaults, editing or rejecting stored insights, generated-output portability, pricing by region, and independent evidence beyond the bounded index review.
Patient agency assessment
Who sets and changes the goal?
Users can set the agenda and decline training participation as documented. No direct mechanism for overriding persistent psychological characterizations was established.
What can the patient understand, question, or do?
Reflection and pattern suggestions may expand understanding, but claims that an AI has found a personal pattern need inspectable evidence and opportunities to disagree. Friendly language and engagement are insufficient proof.
Can the patient evaluate the conditions of use?
The revised policy and EULA are materially clearer about data use. Generated-content reuse and the basis of personal insights remain less clear than input ownership.
Text findings
Conditions of use
Published controls and their limits
The revised policy and EULA are materially clearer about data use. Generated-content reuse and the basis of personal insights remain less clear than input ownership.
What remains unknown?
Not tested or not established
Actual consent defaults, editing or rejecting stored insights, generated-output portability, pricing by region, and independent evidence beyond the bounded index review.
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
- https://www.talktoash.com/
- https://www.talktoash.com/privacy
- https://www.talktoash.com/terms
- https://www.talktoash.com/clinical-research
Source-specific findings and retrieval limitations are recorded in the full report.
Earlier review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Actual consent defaults, editing or rejecting stored insights, generated-output portability, pricing by region, and independent evidence beyond the bounded index review. No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Earlier review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
Document-based draft · Medium for updated rights and scope (AI-assisted draft)